Combination Therapy for Cancer: Oral Fenretinide and Ketoconazole
- Detailed Technology Description
- TechSummary: This inventioncombines fenretinide with metabolic degradation inhibitors offenretinide to increase the therapeutic effect of fenretinide as an anti-cancerdrug.
- Countries
- United States
- Application No.
- PCT/US2008/011207
- *Abstract
-
Background: Oral Fenretinide (4-hydroxy(phenyl) retinamide), a synthetic retinoid derivative which has been investigated for potential use in the treatment of cancer and some other diseases.
Sub-optimal bioavailability of traditional fenretinide formulations has been a limitation for achieving high efficacy.
Technology Description: This invention uses metabolic degradation inhibitors of fenretinide to increase the plasma and tissue levels of fenretinide.The preliminary data show that ketoconazole, a fenretinide degradation inhibitor, has singular effect in increasing the fenretinide bioavailability and efficacy.
Our pre-clinical data in multiple tumor xenograft models demonstrate the usefulness of this combination as an effective way to improve fenretinide’s therapeutic potential as an anti-cancer agent.
Applications: Cancer treatment
Advantages:- Orally administered
- Improved bioavailability
- Improved anti-tumor activity of fenretinide
Development Stage: Pre-clinical proof of principle data.
IP Protection: PCT application filed PCT/US2008/011207
- *IP Issue Date
- Sep 26, 2008
- *IP Type
- Other Patent
- Country/Region
- USA
